3.35 USD
▼-0.16-4.56%
盘后 3.87 0.00%
2026-09-16
市值
$4.47M
市盈率
—
EPS
-18.06
股息率
—
52 周区间
3.29 – 141.50
成交量
9.81K
Beta
0.71
目标价
—
52W 低 3.2952W 高 141.50
价格走势
公司简介
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.